A recent study has uncovered a groundbreaking treatment approach that combines calorie restriction with the drug dapagliflozin to reverse type 2 diabetes. With 828 million adults worldwide suffering from diabetes and 90% of these cases being type 2, this innovative strategy offers new hope. Traditionally, only about 5% of type 2 diabetes patients achieve remission, but this new combination therapy could significantly improve those odds.
Vero’s thoughts on the news:
The findings of this study are incredibly promising, suggesting that the combination of calorie restriction and dapagliflozin could be a game-changer in the ongoing battle against type 2 diabetes. The use of dapagliflozin, in particular, highlights how pharmaceutical advancements can complement lifestyle changes to produce substantial health benefits. From a technological perspective, this opens up new avenues for developing health apps and digital tools that can help patients effectively manage their dietary intake and medication schedules. Such innovations could enhance patient compliance and lead to better health outcomes, making it an exciting time for both the medical and tech communities.
Source: Type 2 diabetes reversed by calorie restriction, dapagliflozin combo – Medical News Today
Hash: b46f3f40af166d1aa5db2b041dfa48f35b7e6a42afe3755739686e71db90f6fb
